Loading...

Stock Performance

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Bluelayer加速器破解版-极光加速器

July 31, 2024 - Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results July 7, 2024 - Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA) July 2, 2024 - Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Bluelayer加速器破解版-极光加速器

Bluelayer加速器破解版-极光加速器

Investor Relations:
Argot Partners
Sam Martin / Maghan Meyers
(212) 600-1902
Email: sam@argotpartners.com / maghan@argotpartners.com

Media Relations:
Tracy Vineis
(617) 420-4839
Email: media@apellis.com

Bluelayer加速器破解版-极光加速器

Sign up to receive email alerts whenever Apellis Pharmaceuticals, Inc. posts new information to the site. Just enter your email address and click Submit.

Sign Up
加速网络连接 Email Alerts RSS Feeds Contact IR
佛跳墙vp最新版2024极光 改名  蓝加速器  梭影APP下载  佛跳墙永久免费版下载  鸿蒙系统安装google play  小牛加速app官网入口,aox加速器官网,小牛vp加速器,小牛加速器官网aox